Cell and Gene Logistics

1. Beyond mRNA Vaccines – Emerging Applications For Lipid Nanoparticle Delivery Technologies 1/19/2021

   The potential of lipid nanoparticle-based drug delivery technologies to enable a new generation of medicines was made clear in 2020 when the first two mRNA vaccines for COVID-19 were rapidly developed and authorized for emergency use. What other applications are now being explored for such delivery technologies? Dr. Jay Natarajan, Director of R&D, competence center for LNP technology, answers questions in this interview.

2. Clinical Supply Global Optimization: Managing Complex Global Drug Distribution And Expiry 1/12/2021

   A global top-ten pharmaceutical company was sponsoring a complex, 8-year Phase III trial across 43 countries. The Sponsor was under intense pressure to reduce trial costs and leverage internal resources. Ultimately, study sites began to run out of medication. They realized that the trial could be better managed if it was outsourced. 

3. Six Mistakes Pharmaceutical Companies Make When Implementing Serialization 12/21/2020

   This article examines mistakes that are commonly made in the planning and implementation phases of a serialization project, and proposes a solution to avoid each of these issues.

4. Advancing Cell And Gene Therapies 12/17/2020

   Cells used for cell and gene therapies pass through several process steps and have to be managed as well as transported between these stakeholders in a fast, sterile and seamless manner.

5. Covid-19 Impact On Bioprocessing: PART 3 Long-Term Changes 11/6/2020

   Although suppliers have proven themselves rather robust in their dealing with the pandemic and business is continuing generally uninterrupted, there will be significant long-term changes.

6. Enabling Fast, Appropriate Drug Product Supply For Phase 1 Clinical Trials 10/30/2020

   Without the ability to move smoothly from lab concept to manufacture to delivery of GMP clinical supplies to patients, critical milestones could be missed, delaying funding commitments from investors.

7. How a Best-Practice Strategy For Sourcing Ancillary Materials Reduced Risk, Spending and Workload In A Global Diabetes Trial 10/29/2020

   It’s impossible to run a global clinical trial of an investigational diabetes drug without ancillary materials. And as one leading multi-national pharmaceutical company recently learned, managing ancillaries can be a challenge every bit as complex as the trial itself.

8. Delivering Clinical Trial Medications Direct-To-Patient 10/15/2020

   In a perfect world, patients enrolled in clinical trials would live a short distance from the investigator site where they receive their treatment. Unfortunately, that is not always the case. In recent years, the direct-to- patient model, which brings medical procedures to a patient’s home, has emerged as a solution for sponsors to increase patient recruitment and retention in clinical trials.

9. Depot-To-Patient Service Overview 9/22/2020

   This infographic provides an overview of Fisher Clinical’s depot-to-patient solution to support decentralized clinical trials in the US.

10. Low Risk Frozen Distribution Of Single-Use Bags For Bioprocessing 9/21/2020

    This paper will discuss the results of applying an approach using sensors and more suitable material to a frozen shipping study of single-use fluoropolymer bags.